Lexicon Pharmaceuticals Company Profile (NASDAQ:LXRX)

Analyst Ratings

Consensus Ratings for Lexicon Pharmaceuticals (NASDAQ:LXRX) (?)
Ratings Breakdown: 3 Hold Rating(s), 2 Buy Rating(s)
Consensus Rating:Hold (Score: 2.40)
Consensus Price Target: $20.13 (27.78% upside)

Analysts' Ratings History for Lexicon Pharmaceuticals (NASDAQ:LXRX)
Show:
DateFirmActionRatingPrice TargetActions
5/31/2016WedbushBoost Price TargetOutperform$28.00 -> $30.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/5/2016JPMorgan Chase & Co.Reiterated RatingHold$16.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/4/2016Needham & Company LLCReiterated RatingBuy$21.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/3/2016Cowen and CompanyReiterated RatingMarket PerformView Rating Details  Tweet This Rating  Share This Rating on StockTwits
9/28/2015GabelliUpgradeSell -> Hold$13.50View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/5/2015Stifel NicolausLower Price TargetBuy$3.50 -> $3.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/25/2014 forward)

Earnings

Earnings History for Lexicon Pharmaceuticals (NASDAQ:LXRX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/5/2016        
5/3/2016Q1($0.30)($0.34)$11.11 million$12.50 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/1/2016Q415($0.38)$0.76$21.50 million$127.30 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/6/2015Q3($0.36)($0.34)$0.45 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/7/2015Q215($0.32)($0.27)$0.45 million$376.00 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
4/29/2015Q115($0.04)($0.04)$1.10 million$1.78 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/4/2014Q3($0.05)($0.08)$0.16 million$0.40 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/7/2014Q214($0.05)($0.05)$0.13 million$0.68 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/8/2014Q114($0.05)($0.06)$0.12 million$277.00 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/28/2014Q413($0.06)($0.03)$1.66 million$1.40 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/12/2013Q3($0.01)($0.06)$1.59 million$0.24 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/21/2013Q4 2012($0.05)($0.05)$0.37 million$0.22 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/6/2012Q312($0.06)($0.06)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Lexicon Pharmaceuticals (NASDAQ:LXRX)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20161($0.37)($0.37)($0.37)
Q2 20161($0.35)($0.35)($0.35)
Q3 20161($0.46)($0.46)($0.46)
Q4 20161($0.18)($0.18)($0.18)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Lexicon Pharmaceuticals (NASDAQ:LXRX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Lexicon Pharmaceuticals (NASDAQ:LXRX)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
6/6/2016James F TessmerVPSell1,500$15.00$22,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/23/2016James F TessmerVPSell6,000$13.00$78,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/12/2014C.V. InvusDirectorBuy150,000$0.88$132,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/10/2014C.V. InvusDirectorBuy315,896$0.90$284,306.40View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/26/2014International S.C.A. ArtalDirectorBuy149,253,731$1.01$150,746,268.31View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/23/2012International S.C.A. ArtalDirectorBuy3,000,000$2.25$6,750,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Lexicon Pharmaceuticals (NASDAQ:LXRX)
DateHeadline
07/23/16 09:00 AMEarnings Focus and Crowd Sourced Sentiment Review for Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) - TGP
07/18/16 05:11 PMLexicon Announces The Validation By The European Medicine Agency Of The Marketing Authorization Application …
07/18/16 03:02 PM4:02 pm Lexicon Pharma announces the acceptance of the filing submitted by Ipsen (IPSEY) to the EMA for telotristat etiprate as an adjunct to somatostatin analog therapy for the long-term treatment of c -
07/18/16 03:01 PMLexicon Announces The Validation By The European Medicine Agency Of The Marketing Authorization Application For Telotristat Etiprate For The Treatment Of Carcinoid Syndrome - [PR Newswire] - THE WOODLANDS, Texas, July 18, 2016 /PRNewswire/ -- Lexicon Pharmaceuticals, Inc. (LXRX) today announced the acceptance of the filing submitted by Ipsen to the European Medicines Agency (EMA) for telotristat etiprate as an adjunct to somatostatin analog therapy for the long-term treatment of carcinoid syndrome. Carcinoid syndrome is a rare disease affecting thousands of cancer patients with metastatic neuroendocrine tumors (mNETs) that have spread to the liver and other organs from the gastrointestinal tract. The condition is characterized by frequent and debilitating diarrhea that often prevents patients from leading active, predictable lives, as well as facial flushing, abdominal pain, fatigue and, over time, heart valve damage.
07/18/16 10:21 AMShares Moving Down on the Week: Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) - Engelwood Daily
07/18/16 10:21 AMStock in Positive Territory for the Quarter: Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) - Engelwood Daily
07/18/16 10:21 AMTrading Performance and Target Watch for Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) - Press Telegraph
07/18/16 10:21 AMShare Performance Summary for: Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) - Press Telegraph
07/15/16 09:23 AMCrowd Rating and Earnings Recap for Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) - Telanagana Press
07/14/16 08:38 AMAnalyst Target and Average Rating Watch: Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) - Press Telegraph
07/14/16 08:38 AMCould Lexicon Pharmaceuticals, Inc. Change Direction After Today's Huge Decline? - Consumer Eagle
07/14/16 08:38 AMIntraday Active Biotech Stocks News: Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX), Sage Therapeutics, Inc ... - The Voice Registrar
07/12/16 05:17 PMShares Moving Up Over the Past Quarter: Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) - Engelwood Daily
07/10/16 04:33 PMBroker Outlook For The Week Ahead Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) - Fiscal Standard
07/09/16 08:25 AMLexicon Pharmaceuticals Incorporated (NASDAQ:LXRX) Sellers Increased By 1.53% Their Shorts - Engelwood Daily
07/08/16 07:56 AMFast Growth for Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) - Telanagana Press
07/07/16 03:31 PMLexicon to Present at the Cantor Fitzgerald Healthcare Conference - [at noodls] - The Woodlands, Texas, July 7, 2016 - Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) announced today that Lexicon management will present at the 2nd Annual Cantor Fitzgerald Healthcare Conference on Wednesday, ...
07/07/16 07:57 AMLexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Current Analyst Ratings - Fiscal Standard
07/06/16 09:42 AMStock Tracking Down This Month; Investor Alert on Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) - Engelwood Daily
07/06/16 09:42 AMLexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Broker Price Targets For The Coming Week - Fiscal Standard
07/06/16 09:42 AMFast Growing Stock: Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) - Telanagana Press
07/03/16 04:34 PMShare Performance Recap for: Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) - Press Telegraph
06/29/16 04:57 PMLexicon Pharmaceuticals, Inc. Stock Momentum Hits Strength - CML News
06/29/16 04:57 PMWhat's Ahead for Lexicon Pharmaceuticals, Inc. After Today's Huge Increase? - Engelwood Daily
06/27/16 09:23 AMNext Weeks Broker Price Targets For Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) - Fiscal Standard
06/27/16 09:23 AMEquity Research and Technical Review on Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) - Press Telegraph
06/27/16 09:23 AMStock Performance Focus on: Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) - Press Telegraph
06/22/16 09:00 AMFrank Palantoni joins Laboratoire M2 as CEO - [GlobeNewswire] - SHERBROOKE, Québec, June 22, 2016-- Laboratoire M2, the company behind THYMOX™, the new standard in environmentally sustainable disinfecting technologies, is proud to announce that Frank Palantoni, a seasoned ...
06/21/16 04:43 PMRecently Issued Stock Ratings For Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) - Fiscal Standard
06/21/16 12:08 PMETF’s with exposure to Lexicon Pharmaceuticals, Inc. : June 21, 2016 -
06/20/16 07:29 AMLexicon Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : LXRX-US : June 20, 2016 -
06/20/16 06:28 AMLexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Analyst Price Targets For The Coming Week - Fiscal Standard
06/17/16 07:49 AMTrending Analyst Recommended Stock: Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) - News Oracle
06/13/16 07:55 AMStock's Price Moves: Cerus Corporation (NASDAQ:CERS) , Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) - Street Updates
06/12/16 07:47 AMWill Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Surprise Analysts? - Investor Newswire
06/09/16 05:18 PMLexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Fundamental Star Rating Report - CML News
06/09/16 12:27 PMETF’s with exposure to Lexicon Pharmaceuticals, Inc. : June 9, 2016 -
06/08/16 08:50 AMLexicon Pharmaceuticals, Inc. :LXRX-US: Earnings Analysis: Q1, 2016 By the Numbers : June 8, 2016 -
06/06/16 04:56 PMLEXICON PHARMACEUTICALS INC. (NASDAQ:LXRX) Financial Condition Compared to S&P 500 - CML News
06/06/16 08:12 AMPremarket Research Report Covering the Biotech Industry -
06/05/16 05:03 PMPerformance Review for Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) - HNN
06/03/16 05:28 PMLexicon Pharma (LXRX) Launches New Carcinoid Syndrome Disease Education Website - StreetInsider.com
06/02/16 05:22 PMWedbush Analysts Reduce Earnings Estimates for Lexicon Pharmaceuticals, Inc. (LXRX) - Let Me Know About This - Wedbush Analysts Reduce Earnings Estimates for Lexicon Pharmaceuticals, Inc. (LXRX)Let Me Know About ThisLexicon Pharmaceuticals logo Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) – Research analysts at Wedbush dropped their FY2016 earnings estimates for shares of Lexicon Pharmaceuticals in a research report issued on Tuesday, according to Zacks ...Lexicon Pharma (LXRX) Launches New Carcinoid Syndrome Disease Education WebsiteStreetInsider.comall 3 news articles »
06/02/16 03:55 PMLexicon Announces the Launch of AboutCarcinoid.com to Provide Carcinoid Syndrome Disease Education to Patients, Caregivers and Physicians - [at noodls] - Commencement of the Carcinoid Syndrome Impact Survey The Woodlands, Texas, June 2, 2016 - Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced the launch of www.aboutcarcinoid.com to provide carcinoid ...
06/02/16 07:54 AMSummary of Price Movements: Novo Nordisk A/S (NYSE:NVO) , Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) - Street Updates - Summary of Price Movements: Novo Nordisk A/S (NYSE:NVO) , Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX)Street UpdatesIn the past trading session, Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) ended trading session higher at $14.54 with +2.32%. The company traded a volume of 961.76 thousand shares as comparison to average volume of 758.6 thousand shares. During ...
06/01/16 07:52 AMNews Sentiment For Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) - Investor Newswire - News Sentiment For Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX)Investor NewswireLexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Average broker stands at 2.4 while it was 2.4 three months ago. The quarterly report of Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) can be made public close to 2016-08-05. It is estimated by the recent ...and more »
06/01/16 07:52 AMStock Update (NASDAQ:LXRX): Lexicon Pharmaceuticals, Inc. Announces FDA Priority Review of New Drug ... - Smarter Analyst - Smarter AnalystStock Update (NASDAQ:LXRX): Lexicon Pharmaceuticals, Inc. Announces FDA Priority Review of New Drug ...Smarter AnalystLexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) announced that the U.S. Food and Drug Administration has accepted for filing the New Drug Application for telotristat etiprate, an oral drug for the treatment of carcinoid syndrome. The FDA has granted a ...Wedbush Boosts Lexicon Pharmaceuticals, Inc. (LXRX) Price Target to $30.00The Cerbat GemLexicon Pharma Says FDA Accepts Carcinoid Syndrome Treatment NDA For Priority Review; Shares Rise 3 ...Sonoran Weekly Reviewall 6 news articles »
05/31/16 05:13 PMStock Review and Earnings Check on Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) - HNN - Stock Review and Earnings Check on Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX)HNNInvestors and analysts are typically super focused on company earnings numbers when they are reported. Company earnings are a good way to evaluate the company profitability. Currently, sell-side analysts are expecting Lexicon Pharmaceuticals, Inc.and more »
05/31/16 09:11 AMLexicon Pharma (LXRX) Announces FDA Priority Review of NDA For Telotristat Etiprate for Treatment of Carcinoid Syndrome - Claim your 2-week free trial to StreetInsider Premium here. Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that the U.S. Food and Drug Administration has accepted for filing the New Drug Application for telotristat etiprate, an oral drug for ...
05/30/16 09:58 PMLexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) 1-Year High At $15.79 - Stocks Daily - Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) 1-Year High At $15.79Stocks DailyThe technical analysis of Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) highlights the stock is $0.40 points away +3.00% from 50-day MA of $13.28. It is $1.65 or +13.69% away $12.03, the stock's 200-day MA. Yesterday, the stock of Lexicon ...Are Analysts Bearish Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) After Last Week?Franklin IndependentAfter Last Week What Do Analysts Think Of Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX)Share Trading NewsLexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) One-Year Price Target At $20.10Markets Dailyall 11 news articles »

Social

About Lexicon Pharmaceuticals

Lexicon Pharmaceuticals logoLexicon Pharmaceuticals, Inc. (Lexicon) is a biopharmaceutical company. The Company focuses on the development of treatments for human disease. The Company is engaged in the development of two drug candidates: telotristat etiprate (LX1032) and sotagliflozin (LX4211). The Company's telotristat etiprate, is an orally delivered small molecule drug candidate, as a treatment for carcinoid syndrome. LX1032 inhibits tryptophan hydroxylase (TPH), which is an orally-delivered small molecule compound that the Company is developing for the treatment of carcinoid syndrome. Sotagliflozin, or LX4211, which is an orally-delivered small molecule compound that the Company is developing for the treatment of type 1 and type 2 diabetes mellitus. LX2761 is an orally-delivered small molecule compound for the treatment of diabetes. LX9211 is an orally-delivered small molecule compound for the treatment of neuropathic pain. The Company's other programs include LX1033, LX2931 and LX7101.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Exchange: NASDAQ
  • Symbol: LXRX
  • CUSIP: 52887210
Key Metrics:
  • Previous Close: $15.75
  • 50 Day Moving Average: $14.39
  • 200 Day Moving Average: $12.35
  • P/E Ratio: N/A
  • P/E Growth: -0.19
  • Market Cap: $1.64B
  • Beta: 1.4
  • Current Year EPS Consensus Estimate: $-1.55 EPS
  • Next Year EPS Consensus Estimate: $-1.78 EPS
Additional Links:
Lexicon Pharmaceuticals (NASDAQ:LXRX) Chart for Monday, July, 25, 2016